Pegylated-interferon alpha 2a treatment for chronic hepatitis C in patients on chronic haemodialysis

World Journal of Gastroenterology

Volumn 12, Issue 26, 2006, Pages 4191-4194

  Sporea, Ioan ^a   Popescu, Alina ^a   Şirli, Roxana ^a   Golea, Ovidiu ^b   Totolici, Camelia ^b   Dǎnilǎ, Mirela ^a   Vernic, Corina ^a  

^a VICTOR BABES UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^b Clinical Emergency County Hospital Pius Brinzeu Timisoara   (Romania)

Author keywords

Biochemical response; Chronic hepatitis C; Haemodialysis; Pegylated interferon alpha 2a; Virological response

Indexed keywords

AMINOTRANSFERASE; HEPATITIS C ANTIBODY; PEGINTERFERON ALPHA2A; VIRUS RNA;

ADULT; ARTICLE; BLEEDING; CATHETER INFECTION; CHRONIC HEPATITIS; CLINICAL ARTICLE; CLINICAL TRIAL; DOSE RESPONSE; DRUG DOSE REDUCTION; EPISTAXIS; FEMALE; FLU LIKE SYNDROME; HEMODIALYSIS; HEMODIALYSIS PATIENT; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LEUKOPENIA; MALE; METRORRHAGIA; MONOTHERAPY; NONHUMAN; REAL TIME POLYMERASE CHAIN REACTION; SEPSIS; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT OUTCOME; VIREMIA; VIRUS LOAD;

EID: 33748592811     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v12.i26.4191     Document Type: Article

References (31)

1. Lombardi M, Cerrai T, Geatti S, Negroni S, Pertusini L, Pegoraro M, Di Lullo G. Results of a national epidemiological investigation on HCV infection among dialysis patients. (Survey by the Italian Branch of EDTNA/ERCA). J Nephrol 1999; 12: 322-327
2. Salama G, Rostaing L, Sandres K, Izopet J. Hepatitis C virus infection in French hemodialysis units: a multicenter study. J Med Virol 2000; 61: 44-51
3. Jadoul M, Cornu C, van Ypersele de Strihou C. Universal precautions prevent hepatitis C virus transmission: a 54 month follow-up of the Belgian Multicenter Study. The Universitaires Cliniques St-Luc (UCL) Collaborative Group. Kidney Int 1998; 53: 1022-1025
4. Schneeberger PM, Keur I, van der Vliet W, van Hoek K, Boswijk H, van Loon AM, van Dijk WC, Kauffmann RH, Quint W, van Doorn LJ. Hepatitis C virus infections in dialysis centers in The Netherlands: a national survey by serological and molecular methods. J Clin Microbiol 1998; 36: 1711-1715
5. Tokars JI, Frank M, Alter MJ, Arduino MJ. National surveillance of dialysis-associated diseases in the United States, 2000. Semin Dial 2002; 15: 162-171
6. Fabrizi F, Dulai G, Dixit V, Bunnapradist S, Martin P. Meta-analysis: interferon for the treatment of chronic hepatitis C in dialysis patients. Aliment Pharmacol Ther 2003; 18: 1071-1081
7. Saxena AK, Panhotra BR, Naguib M, Aboras MN, Sundaram DS, Venkateshappa CK, Khan WU. Prevalence of hepatitis C antibodies among haemodialysis patients in Al-Hasa Region of Saudi Arabia. Saudi J Kidney Dis Transplant 2001; 12: 562-565
8. Jaiswal SK, Chitnis DS, Salgia P, Sepaha A, Pandit CS. Prevalence of hepatitis viruses among chronic renal failure patients on haemodialysis in Central India. Dial Transplant 2002; 31: 234-240
9. Yilmaz ME, Kara IH, Sari Y, Duzen S, Usul Y, Isikoglu B. Seroprevalence and risk factors of HCV in dialysis patients in a university haemodialysis center of southeast Anatolia, Turkey. Dial Transplant 2001; 30: 748-755
10. Fabrizi F, Poordad FF, Martin P. Hepatitis C infection and the patient with end-stage renal disease. Hepatology 2002; 36: 3-10
11. Okuda K, Hayashi H, Kobayashi S, Irie Y. Mode of hepatitis C infection not associated with blood transfusion among chronic hemodialysis patients. J Hepatol 1995; 23: 28-31
12. dos Santos JP, Loureiro A, Cendoroglo Neto M, Pereira BJ. Impact of dialysis room and reuse strategies on the incidence of hepatitis C virus infection in haemodialysis units. Nephrol Dial Transplant 1996; 11: 2017-2022
13. Zampieron A, Jayasekera H, Elseviers M, Lindley E, De Vos JY, Visser R, Harrington M. European study on epidemiology and the management of HCV in the haemodialysis population--Part 1: centre policy. EDTNA ERCA J 2004; 30: 84-90
14. Furusyo N, Kubo N, Nakashima H, Kashiwagi K, Etoh Y, Hayashi J. Confirmation of nosocomial hepatitis C virus infection in a hemodialysis unit. Infect Control Hosp Epidemiol 2004; 25: 584-590
15. Izopet J, Sandres-Saune K, Kamar N, Salama G, Dubois M, Pasquier C, Rostaing L. Incidence of HCV infection in French hemodialysis units: a prospective study. J Med Virol 2005; 77: 70-76
16. Martin P, Carter D, Fabrizi F, Dixit V, Conrad AJ, Artinian L, Peacock V, Han S, Wilkinson A, Lassman CR, Danovitch G. Histopathological features of hepatitis C in renal transplant candidates. Transplantation 2000; 69: 1479-1484
17. Magnone M, Holley JL, Shapiro R, Scantlebury V, McCauley J, Jordan M, Vivas C, Starzl T, Johnson JP. Interferon-alpha-induced acute renal allograft rejection. Transplantation 1995; 59: 1068-1070
18. Rostaing L, Izopet J, Baron E, Duffaut M, Puel J, Durand D. Treatment of chronic hepatitis C with recombinant interferon alpha in kidney transplant recipients. Transplantation 1995; 59: 1426-1431
19. Kamar N, Sandres-Saune K, Selves J, Ribes D, Cointault O, Durand D, Izopet J, Rostaing L. Long-term ribavirin therapy in hepatitis C virus-positive renal transplant patients: effects on renal function and liver histology. Am J Kidney Dis 2003; 42: 184-192
20. Kamar N, Toupance O, Buchler M, Sandres-Saune K, Izopet J, Durand D, Rostaing L. Evidence that clearance of hepatitis C virus RNA after alpha-interferon therapy in dialysis patients is sustained after renal transplantation. J Am Soc Nephrol 2003; 14: 2092-2098
21. Tan AC, Brouwer JT, Glue P, van Leusen R, Kauffmann RH, Schalm SW, de Vries RA, Vroom B. Safety of interferon and ribavirin therapy in haemodialysis patients with chronic hepatitis C: results of a pilot study. Nephrol Dial Transplant 2001; 16: 193-195
22. Sporea I, Golea O, Ursu C, Totolici C, Popescu A, Sirli R et al. Effect of alpha 2b Interferon Treatment in Haemodialysis Patients with Chronic C hepatitis. Rom J Gastroenterol 2001; 4: 285-288
23. Bruchfeld A, Stahle L, Andersson J, Schvarcz R. Ribavirin treatment in dialysis patients with chronic hepatitis C virus infection--a pilot study. J Viral Hepat 2001; 8: 287-292
24. Rostaing L. Treatment of hepatitis C virus infection after renal transplantation: new insights. Nephrol Dial Transplant 2000; 15 Suppl 8: 74-76
25. Rostaing L, Izopet J, Moussion F, Alric L, Verdier D, That HT, Duffaut M, Durand D, Puel J, Suc JM. HCV RNA clearance after treatment with interferon-alpha in chronic hemodialysis patients with or without coinfection by HGV/HGBV-C. Nephrologie 1997; 18: 281-286
26. Izopet J, Rostaing L, Moussion F, Alric L, Dubois M, That HT, Payen JL, Duffaut M, Durand D, Suc JM, Puel J. High rate of hepatitis C virus clearance in hemodialysis patients after interferon-alpha therapy. J Infect Dis 1997; 176: 1614-1617
27. Huraib S, Iqbal A, Tanimu D, Abdullah A. Sustained virological and histological response with pretransplant interferon therapy in renal transplant patients with chronic viral hepatitis C. Am J Nephrol 2001; 21: 435-440
28. Martin P, Mitra S, Farrington K, Martin NE, Modi WN. Pegylated (40ku) Interferon alpha 2a (Pegasys) is unaffected by renal impairment (Abstract). Hepatology 2000; 32: 842
29. Russo MW, Ghalib R, Sigal S, Joshi V. Randomized trial of pegylated interferon alpha-2b monotherapy in haemodialysis patients with chronic hepatitis C. Nephrol Dial Transplant 2006; 21: 437-443
30. Potthoff A, Wiegand J, Luth JB, Wedemeyer H, Manns MP, Tillmann HL. Superiority of standard interferon-alpha2b compared to pegylated interferon-alpha2b (12 kDa) in a hemodialysis patient with chronic hepatitis C? Clin Nephrol 2005; 63: 232-235
31. Mahmoud IM, Sobh MA, El-Hayashi AF, Sally ST, El-Baz M, El-Sawy E, Ghoneim MA. Interferon therapy in hemodialysis patients with chronic hepatitis C: study of tolerance, efficacy and post-transplantation course. Nephron Clin Pract 2005; 100: c133-139